Gilead baits new alliance with $45M upfront, diving into the busy protein degradation field
Gilead is jumping on board the protein degradation bandwagon. And they’re turning to a low-profile Third Rock startup for the expertise. But if you were looking for a transformational deal to kick up fresh enthusiasm for Gilead, you’ll have to remain patient.
This one will have a long way to go before they get into the clinic.
The big biotech said Wednesday morning that it is paying $45 million upfront and reserving a whopping $2.3 billion in biotech bucks if San Francisco-based Nurix can point the way to new cancer therapies, as well as drugs for other, unspecified diseases.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters